CD22 and non-Hodgkin lymphoma: Li T et al. [48] conducted a study with a “cocktail” strategy of anti-CD19 and anti-CD22 CAR-T cell infusion in a small number of patients with R/R B-NHL with CNS involvement, obtaining short-lasting responses in two out of five patients.